Condition (MeSH)
Ichthyosis, Lamellar
ClinicalTrials.gov lists 7 trials for Ichthyosis, Lamellar or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 7 trials are tagged with Ichthyosis, Lamellar itself; the rest are tagged with a narrower condition beneath it.
When did Ichthyosis, Lamellar trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2019 | 1 |
| 2016 | 1 |
| 2010 | 1 |
| 2006 | 1 |
| 1994 | 1 |
| 1992 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ichthyosis, Lamellar trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Observational | 3 |
How many Ichthyosis, Lamellar trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Completed | 5 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ichthyosis, Lamellar trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Mayne Pharma International Pty Ltd | 1 |
| National Cancer Institute (NCI) | 1 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
| Stiefel, a GSK Company | 1 |
Which serious adverse events do Ichthyosis, Lamellar trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalization-GERD | 2 | 1 |
| Hospitalization-pyelonephritis | 1 | 1 |
Which publications cover Ichthyosis, Lamellar? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Secukinumab responses vary across the spectrum of congenital ichthyosis in adults. | Archives of dermatological research | 2023 | Yes |
| Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. | The Journal of clinical investigation | 2017 | Yes |
| Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial. | The British journal of dermatology | 2014 | Yes |
| Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. | Nature genetics | 1995 | Yes |
| [Non-cirrhotic ascites: pathophysiology, diagnosis and etiology]. | La Revue de medecine interne | 2014 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Lamellar ichthyosis | Point prevalence | 1-9 / 1 000 000 | Spain | Not stated | Exact |
| Lamellar ichthyosis | Point prevalence | 1-9 / 100 000 | Norway | Not stated | Exact |
| Lamellar ichthyosis | Point prevalence | 1-9 / 100 000 | Norway | Not stated | Exact |
| Lamellar ichthyosis | Point prevalence | 1-9 / 1 000 000 | Spain | Not stated | Exact |
| Lamellar ichthyosis | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Lamellar ichthyosis | 313 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Lamellar ichthyosis | 313 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.